Administrative, Regulatory and Cord Blood Bank

行政、监管和脐带血库

基本信息

项目摘要

The goals of this core are to provide all projects and the other cores with centralized leadership, administrative. Cord Blood Bank and clinical research support. The Administrative component will be responsible for integrating all components of the program project grant (PO1) and overseeing progress, so that the research objectives are being met. It will provide assistance to each project and core leader with budgetary issues and will oversee the overall fiscal and budgetary management of the program. This Core will also coordinate oversight of the PO1 by convening meetings of the Internal and External Advisory Boards and implementing their recommendations. The goals of the clinical research component of this core are to provide all projects with clinical trial support in collaboration with Core B and provide an infrastructure of personnel and services that will adequately support such research. Core services will be provided in regulatory affairs, study coordination, quality assurance and control and data safety monitoring. The Regulatory Affairs component collaborates with investigators to develop and submit all required regulatory documents, including submissions to the IRB, IBC, FDA, and NIH/OBA and annual reports. This core has extensive experience with IND submission and currently supports over 45 IND studies. The Quality Control program will ensure that standard operating procedures for protocol development, conduct of clinical trials, data collection and management of clinical trials are accurately defined and being followed. The Quality Assurance program will undertake audits after the first patient is enrolled on a study and then randomly to ensure that the studies are being conducted according to Good Clinical Practices. The MD Anderson Cord Blood Bank is committed to providing cord blood units for pre-clinical peer-reviewed research to advance the field of cord blood transplantation, and will provide all the cord blood units needed to execute the studies proposed in the projects. In this PO1 we have developed strategic approaches to overcome the limitations of cord blood transplantation and will rely on testing potential solutions in carefully designed preclinical models and then translating the results to the clinic.
该核心的目标是为所有项目和其他核心提供集中的领导,管理。脐带血库和临床研究支持。行政部门将负责整合计划项目拨款(PO1)的所有组成部分,并监督进展情况,以实现研究目标。它将为每个项目和核心负责人提供预算问题方面的协助,并将监督该计划的整体财政和预算管理。该核心还将通过召开内部和外部咨询委员会会议并执行其建议来协调对行动纲领1的监督。该核心的临床研究部分的目标是与核心B合作,为所有项目提供临床试验支持,并提供充分支持此类研究的人员和服务基础设施。在监管事务、研究协调、质量保证和控制以及数据安全监测等方面提供核心服务。监管事务组件与调查人员合作,制定并提交所有所需的监管文件,包括提交给IRB, IBC, FDA和NIH/OBA以及年度报告。该核心在IND提交方面拥有丰富的经验,目前支持超过45项IND研究。质量控制项目将确保方案制定、临床试验实施、数据收集和临床试验管理的标准操作程序得到准确定义和遵循。质量保证项目将在第一名患者入组研究后进行审核,然后随机进行审核,以确保研究按照良好临床规范进行。MD安德森脐带血库致力于为临床前同行评审研究提供脐带血单位,以推进脐带血移植领域,并将提供执行项目中提出的研究所需的所有脐带血单位。在本项目中,我们开发了克服脐带血移植局限性的战略方法,并将依靠在精心设计的临床前模型中测试潜在的解决方案,然后将结果转化为临床。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elizabeth J Shpall其他文献

Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome
  • DOI:
    10.1182/blood-2022-159336
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Oren Pasvolsky;Rima M. Saliba;Uday R Popat;Amin M Alousi;Rohtesh S. Mehta;Jason Yeh;Gheath Alatrash;Adeel Masood;Jeremy L. Ramdial;Gabriela Rondon;Partow Kebriaei;Richard E Champlin;Elizabeth J Shpall;Betul Oran
  • 通讯作者:
    Betul Oran
Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
  • DOI:
    10.1182/blood-2022-166381
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Rohtesh S. Mehta;Rima M. Saliba;Amin M Alousi;Gheath Alatrash;Qaiser Bashir;Chitra Hosing;Partow Kebriaei;Issa F. Khouri;Yago Nieto;Betul Oran;Uday R Popat;Muzaffar H Qazilbash;Jeremy L. Ramdial;Gabriela Rondon;Samer A Srour;Katy Rezvani;Richard E Champlin;Elizabeth J Shpall;Kai Cao
  • 通讯作者:
    Kai Cao
Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy
  • DOI:
    10.1182/blood-2022-166783
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Andrew Jallouk;Lei Feng;Mansoor Noorani;Kaberi Das;Raphael E Steiner;Loretta J. Nastoupil;Misha Hawkins;Ranjit Nair;Jason Westin;Luis Fayad;Dai Chihara;Luis Enrique Malpica Castillo;Swaminathan P. Iyer;Sairah Ahmed;Elizabeth J Shpall;Partow Kebriaei;Sattva S. Neelapu;Paolo Strati
  • 通讯作者:
    Paolo Strati
Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
  • DOI:
    10.1182/blood-2022-166472
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Rohtesh S. Mehta;Rima M. Saliba;Amin M Alousi;Gheath Alatrash;Qaiser Bashir;Partow Kebriaei;Issa F. Khouri;Yago Nieto;Betul Oran;Uday R Popat;Muzaffar H Qazilbash;Jeremy L. Ramdial;Gabriela Rondon;Samer A Srour;Katy Rezvani;Richard E Champlin;Elizabeth J Shpall;Kai Cao
  • 通讯作者:
    Kai Cao
Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
  • DOI:
    10.1182/blood-2022-165780
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Jason Yeh;Rima M. Saliba;Christopher Wang;Zhou Fang;Bradley Figgins;Sairah Ahmed;Musa Yilmaz;Naval Daver;Rohtesh S. Mehta;Gheath Alatrash;David Marin;Uday R Popat;Richard E Champlin;Elizabeth J Shpall;Betul Oran
  • 通讯作者:
    Betul Oran

Elizabeth J Shpall的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elizabeth J Shpall', 18)}}的其他基金

SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
  • 批准号:
    10911713
  • 财政年份:
    2023
  • 资助金额:
    $ 47.07万
  • 项目类别:
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
  • 批准号:
    10478151
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Cord Blood Expansion and Homing to Improve Engraftment
脐带血扩张和归巢以改善植入
  • 批准号:
    9340308
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10247037
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Cord Blood Expansion and Homing to Improve Engraftment
脐带血扩张和归巢以改善植入
  • 批准号:
    8555381
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Cord Blood Graft Engineering to Improve Engraftment and Reduce GVHD
脐带血移植工程可改善移植并减少 GVHD
  • 批准号:
    10247041
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Administrative, Regulatory and Cord Blood Bank
行政、监管和脐带血库
  • 批准号:
    8555385
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10478144
  • 财政年份:
    2011
  • 资助金额:
    $ 47.07万
  • 项目类别:
Good Manufacturing Practice (GMP) and Immune Assessment Core
良好生产规范 (GMP) 和免疫评估核心
  • 批准号:
    8000169
  • 财政年份:
    2010
  • 资助金额:
    $ 47.07万
  • 项目类别:
DETECTION OF MALIGNANT CELLS IN MARROW & PBPC FRACTIONS
骨髓中恶性细胞的检测
  • 批准号:
    2863385
  • 财政年份:
    1998
  • 资助金额:
    $ 47.07万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.07万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了